News
CADTH is now accepting abstracts for workshops, panels, debates, breakfast sessions, oral presentations, and posters for the 2021 CADTH Symposium to be held online on November 2, 3, and 4.
This year’s theme is Uncertain Times, Imperfect Evidence, and the Imperative to Act. Learn more about the theme.
Abstracts must be submitted online at ...
A new report from Choosing Wisely Canada (CWC) and CADTH looks ahead to post-pandemic health care in Canada. The report highlights consensus on evidence-based recommendations to reduce low-value care when health systems are ready to gradually resume the services and procedures that were put on hold due to COVID-19.
The joint report, Using Healt...
CADTH and Choosing Wisely Canada have convened a group of clinicians, policy experts, and patient advisors to identify actions that health systems can take to improve post-pandemic care for Canadians.
The Expert Panel on Post-Pandemic Care is composed of leaders from across the country who bring a range of experience and perspectives to this wo...
A message from Suzanne McGurn, President and CEO of CADTH
On behalf of the team at CADTH, I’m proud and excited to announce that we have launched the Canadian Journal of Health Technologies, a new open-access journal serving the Canadian and global health technology assessment (HTA) community. You can find it online at canjhealthtechnol.ca and ...
Onasemnogene abeparvovec (Zolgensma) is the first gene therapy used to treat spinal muscular atrophy — a rare progressive and life-threatening condition that often begins in childhood and is caused by a genetic mutation.
Conditions for reimbursement include a price reduction and clinical criteria for initiating treatment.
Today, CADTH recom...
